This is a future-proof and randomized controlled clinical study on the clinical efficacyof graphene photothermal adjuvant therapy in Corona Virus Disease 2019(COVID-19) patientswith mild symptoms. The objective is to examine the effect of graphene photothermaladjuvant therapy on the time line for such Corona Virus Disease 2019 patients to achievea negative severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleic acid testresult, and their duration of disease. Patients who meet study criteria will berandomized into the Grapheme adjuvant therapy combined with conventional therapy group(treatment group) and the conventional therapy only group (control group). Contrasted tothe control groups, the treatment groups will undergo 30-min of graphene adjuvant therapyevery day for 7 d.
Following enrollment, patients will be randomized into treatment or control groups. All
groups will receive the same conventional therapy.
In addition, treatment groups will undergo Graphene adjuvant therapy 30 minutes per day
for 7 d.
Upon completion of the treatment protocol, specific study endpoints will be compared
between the treatment and control groups.
Device: Graphene spectrum light wave therapy room
Undergo 30-min of graphene adjuvant therapy every day for 7 d.
Inclusion Criteria:
- Meet the diagnostic criteria for mild COVID-19.
- Patients aged 18-60 years (inclusive).
- No later than 48 h after testing positive and the onset of clinical symptoms
- Sign informed consent form.
Exclusion Criteria:
- Severe or critically patients with COVID-19.
- Resting heart rate over 120 beats per minute.
- Coronary heart disease patients with acute cardiac insufficiency.
- Acute exacerbation of chronic obstructive pulmonary disease（COPD）.
- Uncontrolled hypertension [resting systolic blood pressure(SBP) more than 180 mmHg
and diastolic blood pressure(DBP) more than 90 mmHg]; uncontrolled diabetes(Random
Plasma Glucose, RPG>16.7mmol/L, HbA1C>7.0%)
- Patients with severe cardiovascular, hepatic, renal and hematopoietic diseases.
- Pregnant or menstruating woman.
- Known or suspected history of active tuberculosis or extrapulmonary tuberculosis,
patients with brucellosis, pneumonia-related illness from other causes
- COVID-19 patients for the second or more times
- Those who cannot cooperate due to various reasons
- Body temperature: more than 38℃.
Hohhot First Hospital
Hohhot, Inner Mongolia, China
Investigator: Junjing Zhang
Contact: 086-04175281618
zhang.jj@vip.163.com
Songqiao Liu, PhD.
086-02583262550
liusongqiao@ymail.com
Junjing Zhang
086-04175281618
zhang.jj@vip.163.com
Songqiao Liu, PhD., Study Chair
Southeast University